MDT perspectives on the role of biomarkers in informing immune checkpoint inhibitor use across tumour types
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team review the role of biomarkers in informing immune checkpoint inhibitor use across tumour types.
The multidisciplinary team
Medical oncologist: Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.
For further information visit our website…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.